NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Pfizer
Conditions: Chronic Myeloid Leukaemia
Interventions: Bosutinib, Imatinib, Nilotinib, Dasatinib, Ponatinib
Countries: Hungary
The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary. The primary endpoint of this study is the overall survival of CML patients treated with tyrosine kinase inhibitors in Hungary. The Overall Survival (OS) of all enrolled patients, OS by sequence pattern and by the number of treatment lines will be analyzed. Secondary objectives are description of the treatment length in 1st and later lines, incidence and prevalence of CML, the patient demographics (as age, gender, comorbidities), average number of patients' comorbidities, most frequent comorbidities and patient number with comorbidities at baseline and at different treatment lines by investigated Thyrosine Kinase Inhibitor (TKI), distribution of the investigated TKI therapies by treatment lines
Sex: ALL
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Female and male patients diagnosed with chronic myeloid leukemia * Patients receiving tyrosine kinase inhibitor therapy under the terms of the current marketing authorization Exclusion Criteria: * Patients receiving TKI for non-CML diagnoses
- Budapest, Hungary